Kyverna Therapeutics, Inc.
HealthcareNASDAQ:KYTX · NASDAQ Global Select
+$0.19 today
Vol 0.65M · Avg 0.93M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$156.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.28, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 -100.0% | $7.0M +24.2% | $5.7M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 -100.0% | $2.1M +25.0% | $1.7M | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 +100.0% | -$2.1M -25.0% | -$1.7M -124.3% | $7.0M +24.2% | $5.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $133.7M +18.9% | $112.5M +133.3% | $48.2M +69.8% | $28.4M +9.9% | $25.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $36.1M +19.8% | $30.1M +141.4% | $12.5M +55.9% | $8.0M +30.2% | $6.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $169.8M +20.9% | $140.5M +131.4% | $60.7M +66.7% | $36.4M +13.8% | $32.0M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.8M -15.7% | $2.1M +25.0% | $1.7M +62.4% | $1.1M +79.4% | $586.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$159.0M -27.0% | -$125.2M -114.1% | -$58.5M -110.5% | -$27.8M -7.8% | -$25.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | -395.4% +60.1pp | -455.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$169.8M -19.1% | -$142.6M -128.5% | -$62.4M -112.4% | -$29.4M -11.5% | -$26.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | -418.3% +47.5pp | -465.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $9.1M -40.8% | $15.4M +573.0% | $2.3M +303.9% | $565.0K +56400.0% | $1.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $489.0K +244.4% | $142.0K -24.1% | $187.0K +187.7% | $65.0K +2066.7% | $3.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $8.5M -43.7% | $15.1M +641.5% | $2.0M +315.5% | $491.0K +12375.0% | -$4.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$161.3M -26.5% | -$127.5M -111.2% | -$60.4M -108.9% | -$28.9M -9.7% | -$26.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | -411.3% +54.6pp | -465.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$161.3M -26.5% | -$127.5M -111.2% | -$60.4M -108.9% | -$28.9M -9.7% | -$26.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | -411.3% +54.6pp | -465.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$4 -9.3% | -$3 -3329900.0% | -$0 +100.0% | -$1 -9.8% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$4 -9.3% | -$3 -3329900.0% | -$0 +100.0% | -$1 -9.8% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $44.3M +15.5% | $38.3M -94.3% | $673.6M +2510.5% | $25.8M +0.0% | $25.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $44.3M +15.5% | $38.3M -94.3% | $673.6M +2510.5% | $25.8M +0.0% | $25.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.18B
Cabaletta Bio, Inc.
NASDAQ:CABA
$490.79M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$444.15M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$343.14M
Silence Therapeutics plc
NASDAQ:SLN
$316.00M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$315.01M
Editas Medicine, Inc.
NASDAQ:EDIT
$244.75M
Mereo BioPharma Group plc
MREO
$48.68M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does KYTX generate?
Kyverna Therapeutics, Inc. (KYTX) reported $0.00 of revenue in fiscal 2025.
Is KYTX profitable?
Kyverna Therapeutics, Inc. (KYTX) reported -$161,307,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.